90252361 - P HLA PROTEIN

Information

• Trademark
• 90252361

• Source

• Serial Number

  90252361

• Registration Number

  6828530

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  October 13, 2020
  3 years ago

• Registration Date

  August 23, 2022
  2 years ago

• Transaction Date

  January 26, 2023
  a year ago

• Status Date

  August 23, 2022
  2 years ago

• Published for Opposition Date

  September 07, 2021
  3 years ago

• Location Date

  July 15, 2022
  2 years ago

• First Use Anywhere Date

  January 04, 2021
  3 years ago

• First Use In Commerce Date

  January 04, 2021
  3 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  MANGUBAT, ALEXANDER GE

• Attorney Docket Number

  PPTEN.043T

  Attorney Name

  Ian W. Gillies

  Law Office Assigned Location Code

  N30

• Owners

  • Pure Protein L.L.C.

Case File Statements

• DM0000: The mark consists of a square on top with two squares on each side touching corners with one square on the bottom with the top left section missing and a floating square in the middle of the four squares forming the letter "P" next to the literal word "HLA Protein".
• GS0051: Chemicals and biochemicals for in vitro clinical and medical use
• PM0001: HUMAN LEUKOCYTE ANTIGEN
• GS0011: Reagents for scientific, pharmaceutical, clinical, and medical research purposes; laboratory chemicals, namely, protein-based reagents used for the detection of antibodies and receptors in cell, blood, and tissue analysis for in vitro diagnostics for scientific use and research in the field of therapeutic reagent designs; chemicals and biochemicals in the nature of reactants and reagents for in vitro scientific or research use; chemicals and biochemicals for use in the manufacture of pharmaceutical preparations; chemical, biochemical and biotechnological solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with antibody and B or T cell detection, separation and labelling; biochemical reagents for detecting and analyzing molecules in protein arrays; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; chemical, biochemical and biotechnological products in the nature of reactants and reagents for use in biotechnological product development of therapeutics for the prevention and treatment of cancer, infectious diseases, autoimmune diseases and allergies; chemical, biochemical and biotechnological preparations used in industry and science, and in the development and manufacture of pharmaceuticals, pharmaceutical preparations and substances, for the prevention and treatment of cancer, infectious diseases, autoimmune diseases and allergies; chemical, biochemical and biotechnological preparations used in industry and science, and in the development and manufacture of pharmaceuticals, pharmaceutical preparations and substances, for the detection, prevention and treatment of rejection causing antibodies, B and T cells
• GS0441: Medical consulting services for transplant and organ rejection assessment
• D10000: "HLA PROTEIN"
• GS0421: Providing scientific, pharmaceutical, clinical, and medical research information via the internet; research and development of new products; pharmaceutical drug and biomarker preparation target discovery, development, and validation in the nature of research, development, and quality assurance services; pharmaceutical and scientific research and development services; medical research services; medical development services in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; clinical research services in the fields of pharmaceuticals, biology, chemistry, biochemistry, and clinical trials; clinical development services in the nature of scientific development of clinical trials; consulting services in the field of pharmaceutical assessment; scientific and medical research consulting services for transplant and organ rejection assessment; validation in the nature of quality assurance services, screening and mapping in the nature of scientific research and development of biological material for drug discovery and vaccine manufacturing purposes; providing scientific information and medical research information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; scientific and medical research and development in the field of cancer, infectious diseases, autoimmune diseases and allergies; scientific and medical research and development in the field of antibody, B cell and T cell detection in transplant and organ rejection

Case File Event Statements

• 8/23/2022 - 2 years ago

  28 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 8/23/2022 - 2 years ago

  27 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 7/16/2022 - 2 years ago

  26 - NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Type: SUNA

• 7/15/2022 - 2 years ago

  25 - ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Type: CNPR

• 6/23/2022 - 2 years ago

  24 - STATEMENT OF USE PROCESSING COMPLETE Type: SUPC

• 6/3/2022 - 2 years ago

  23 - USE AMENDMENT FILED Type: IUAF

• 6/23/2022 - 2 years ago

  22 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 6/3/2022 - 2 years ago

  21 - TEAS STATEMENT OF USE RECEIVED Type: EISU

• 5/3/2022 - 2 years ago

  20 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 4/29/2022 - 2 years ago

  19 - SOU EXTENSION 1 GRANTED Type: EX1G

• 4/29/2022 - 2 years ago

  18 - SOU EXTENSION 1 FILED Type: EXT1

• 4/29/2022 - 2 years ago

  17 - TEAS EXTENSION RECEIVED Type: EEXT

• 2/25/2022 - 2 years ago

  16 - ASSIGNED TO EXAMINER Type: DOCK

• 11/2/2021 - 2 years ago

  15 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 9/7/2021 - 3 years ago

  14 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 9/7/2021 - 3 years ago

  13 - PUBLISHED FOR OPPOSITION Type: PUBO

• 8/18/2021 - 3 years ago

  12 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 8/1/2021 - 3 years ago

  11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 5/14/2021 - 3 years ago

  10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 5/14/2021 - 3 years ago

  9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 5/14/2021 - 3 years ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 3/29/2021 - 3 years ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 3/29/2021 - 3 years ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 3/29/2021 - 3 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 3/11/2021 - 3 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 12/3/2020 - 3 years ago

  3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC

• 12/2/2020 - 3 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 10/16/2020 - 3 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP